Canaccord raised the firm’s price target on Cipher Pharmaceuticals (CPHRF) to C$13 from C$12.50 and keeps a Hold rating on the shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPHRF:
- Cipher Pharmaceuticals Reports Strong Revenue Growth in Q1 2025
- Cipher Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
- Cipher Pharmaceuticals Reports Strong Q1 2025 Results and Strategic Debt Repayment
- CPHRF Upcoming Earnings Report: What to Expect?
- Cipher Pharmaceuticals to Announce Q1 2025 Financial Results